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Rats and guinea pigs developed pronounced erythrocytosis at one to four months after
unilateral intrarenal (ir) injection of nickel subsulfide (Ni3S2). For example, at two months
after ir administration of Ni3S2 (5 mg) to rats, blood hematocrit values averaged 70 i 3 per-
cent (p < 0.001 vs. 48 + 2 incontrols); at two months after ir administration ofNi3S2 (20 mg)
to guinea pigs, blood hematocrit values averaged 67 6 percent (p < 0.001 vs. 49 i 1 per-
cent in controls). Hamsters and gerbils did not develop erythrocytosis after irinjection ofNi3S2
(5 mg/animal). Administration ofNi3S2 to rats by intrasplenic injection did not increase blood
hematocrit; splenectomy did not prevent erythrocytosis in rats that received ir injection of
Ni3S2. Erythrocytosis in rats was completely blocked by excision of the Ni3S2-injected kidney
but was unaffected by excision ofthe non-injected kidney. Partial inhibition of Ni3S2-induced
erythrocytosis in rats occurred after simultaneous ir injection of Mn, Cu, or Al dusts,
benzo(a)pyrene, or subcutaneous (sc) infusion of sodium diethyldithiocarbamate. Eryth-
rocytosis induced by ir injection of Ni3S2 was augmented by ir injection of Cr dust or in-
tramuscular (im) administration of iron-dextran. Erythrocytosis occurred in rats after ir im-
plantation of Ni3S2 within semi-permeable cellulose tubules, indicating that phagocytosis of
Ni3S2 particles is unnecessary for erythropoietic stimulation. Erythropoietin (Ep) activity in rat
serum increased sixfold at two weeks after ir injection of Ni3S2 (p < 0.001 vs. controls), but
Ep activity in pooled extracts of Ni3S2-treated rat kidneys did not increase significantly. This
study identifies several factors that influence erythropoietic stimulation by Ni3S2, and furnishes
salient information concerning the pathogenesis of Ni3S2-induced erythrocytosis.
INTRODUCTION
In 1973, Jasmin [11 noted that rats develop polycythemia within one month after
an intrarenal (ir) injection of nickel subsulfide (Ni3S2). Subsequent studies con-
firmed that blood hematocrit, hemoglobin concentration, and erythrocyte count are
significantly increased from one week to approximately six months following ir in-
jection of 5 or 10 mg ofNi3S2 [2-4]. Blood hematocrit values are greatest at six to 12
weeks; highest reticulocyte counts and maximum incorporation of 59Fe into eryth-
rocytes occur at two to four weeks [5-101. Pronounced erythroid hyperplasia is pres-
ent in bone marrow of rats from two weeks to five months after ir injection ofNi3S2
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[3,7,9,10]. In rats that receive ir injection of 5 or 10 mg of Ni3S2, the circulating
erythrocyte mass undergoes 2 to 2.5-fold enlargement; the plasma volume is slightly
diminished, and the concentration of 2,3-diphosphoglycerate in erythrocytes re-
mains normal [2,3,10]. When 51Cr-tagged erythrocytes from Ni3S2-treated rats are
transfused into normal recipients, the circulating half-life of the labelled cells is pro-
longed, consistent with an increased proportion of juvenile erythrocytes [7]. Ni3S2-
induced erythrocytosis is unaccompanied by leukocytosis or thrombocythemia
[3,10]. Erythrocytosis does not occur in rats after administration of Ni3S2 by in-
tramuscular (im), intravenous (iv), or intrahepatic injection, or after sustained in-
traperitoneal (ip) infusion of NiCl2 [3,4,7,8,11].
Induction of erythrocytosis by ir administration seems to be peculiar to nickel
compounds, inasmuch as ir injections of Au, Cd,Co, CoS, Cr, Cu, Fe, Mn, and Pb
dusts do not stimulate erythrocytosis in rats [12,13]. The erythropoietic effects of 17
nickel compounds have been tested by ir administration to rats [13]. In order of
decreasing potency, the following compounds cause significant increases of blood
hematocrit: Ni3S2 > NiO > NiSe > NiS2 > NiS > Ni3Se2 > Ni4FeS4 > Ni dust
> NiAsS [13]. Equivalent doses of the following compounds do not affect blood
hematocrit under the same conditions: amorphous NiS, NiTe, NiAs, Nil,As5,
Ni5As2, NiSb, NiFe, and NiTiO3 [13]. Stimulation of erythropoiesis in rats by ir in-
jection of nickel compounds does not correlate with phagocytosis of the compounds
by rat peritoneal macrophages in vitro [13,14], or dissolution of the compounds dur-
ing incubation in rat serum or renal cytosol [13,15]. Ni3S2-induced erythrocytosis in
rats is inhibited by simultaneous ir injection of Mn dust [16]. Until the present study,
Ni3S2 was known to induce erythrocytosis only in rats; ir injection of Ni3S2 does not
cause erythrocytosis in mice (BALBc strain) or squirrels [7].
Several reports have described the pathological lesions that develop in rats after ir
injection of Ni3S2 [3,7,9,17,18]. Inflammation and fibrosis occur along the needle
tract in the injected kidney [3,7]; Ni3S2-particles are phagocytized by mononuclear
cells and glomerular mesangial cells [9]; renal glomeruli become enlarged [9];
mesangial cells become hyperplastic [9]; and crystalline mitochondrial inclusions
develop in renal tubular cells [17,18]. Carcinomas and sarcomas frequently become
evident in the injected kidneys of rats at eight to 20 months after ir injection of Ni3S2
[4,12,19]. Other pathological findings include splenomegaly, cardiomegaly, sialyl
hyperplasia, and arteriosclerosis [9].
The following evidence suggests that Ni3S2-induced erythrocytosis is mediated by
increased renal production of erythropoietin (Ep): (a) Ep activity is increased in rat
serum at two to eight weeks after ir injection of Ni3S2 [6,10,11]; (b) erythrogenin ac-
tivity is increased in the light mitochondrial fraction from kidneys of Ni3S2-treated
rats[10]; (c) Ni3S2-induced erythrocytosis is reversed by resection of the injected
kidney[10,11]; (d) Ni3S2-induced erythrocytosis is suppressed by prolonged exposure
to hyperoxia[10]; and (e) Ni3S2-induced erythrocytosis is prevented by ip infusion of
anti-Ep antiserum [10].
The present paper describes ten experiments on Ni3S2-induced erythrocytosis that
furnish salient information concerning species-specificity, route of administration,
effects of nephrectomy and splenectomy, inhibition by chelating agents; antagonism
by metal dusts, role of phagocytosis, effect of iron-dextran treatment, response to
simultaneous ir injection of benzo(a)pyrene, and erythropoietin activity in renal
cytosol.
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MATERIALS AND METHODS
Test Materials
Nickel subsulfide (aNi3S2, median particle diameter < 2 /im) was donated by
Stuart Warner, Ph.D., INCO Ltd., Toronto, Canada. The chemical and physical
properties of the Ni3S2 sample were described previously [19,20]. Mn, Cu, Cr, and
Al dusts (median particle diameters < 5 lim) were obtained from Alfa Inorganic
Products Division, Ventron Corp., Danvers, MA. Purity of the metal dusts was
> 99.9 percent, based upon the producer's specifications. Benzo(a)pyrene (Mann
Research Laboratories, Inc., New York, NY) yielded a single fluorescent spot after
thin-layer chromatography, as previously described [21]. Iron-dextran solution
["Imferon," Fe(OH)3-dextran complex (50 mg Fe/ml), dissolved in NaCl solution
(0.14 mol/liter)] was obtained from Richardson Merrill, Inc., Cincinnati, OH.
d-Penicillamine (d-3-mercaptovaline hydrochloride) was obtained from Aldrich
Chemical Co., Milwaukee, WI. Sodium diethyldithiocarbamate trihydrate (Sigma
Chemical Co., St. Louis, MO) was recrystallized, as previously described [22].
Lyophilized sheep erythropoietin ("Stage 3 Preparation," Connaught Laboratories,
Ltd., Swiftwater, PA) was the standard for erythropoietin bioassays.
Experimental Animals
The animals included 596 male rats (Fischer-344 strain, mean body weight = 230
g, SD + 44 g. Charles River Breeding Laboratories, Inc., Wilmington, MA); 120
virgin female mice (CF-I strain, mean body weight = 27 g, SD 2 g, Charles
River Breeding Laboratories, Inc.); 19 male guinea pigs (Hartley strain, mean body
weight = 534 g, SD + 18 g, Buckberg Laboratory Animals, Inc., Tomkins Cove,
NY); 22 male hamsters (Syrian golden strain, mean body weight = 117 g, SD + 13
g. Charles River Breeding Laboratories, Inc.); and 19 male Mongolian gerbils (mean
body weight = 90 g, SD 13 g, bred in the University of Connecticut Vivarium,
Farmington, CT). The animals were fed the appropriate Purina laboratory animal
chows and water ad libitum. Gerbils received parenteral iron supplementation (Im-
feron, 2.5 mg Fe/gerbil, im) at biweekly intervals. Rats and guinea pigs were housed
in stainless steel cages; mice, hamsters, and gerbils were housed in polypropylene
cages with wood chip bedding.
Treatments
Anesthesia with diethylether was used for animal surgery. The kidney was ex-
posed by a subcostal lumbar incision. For ir injection, the test substance [suspended
in 0.1 to 0.25 ml ofNaCl solution (0.14 mol/liter) or glycerol (50 percent solution in
distilled water)] was injected into the kidney by a tuberculin syringe with No. 25
gauge needle. For nephrectomy, the ureter and renal vessels were ligated with silk
sutures, and the kidney was excised with fine scissors. After ir injection or nephrec-
tomy, the lumbar muscles were sutured with silk, and the skin incision was closed
with surgical clips. For intrasplenic injection or splenectomy, similar procedures
were used; the abdominal cavity was opened by a midline incision. In one experi-
ment, osmotically driven pumps ("Alzet minipumps," model 2001, infusion
rate = 1 MLl/hr, Alza Corp., Palo Alto, CA) were employed for sc infusion of
chelating agents, aspreviously described [23]. The pumps werereplaced at seven-day
intervals during the 35 days of treatment. In another experiment, semipermeable
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tubules ("Diaflo H1OX50 Fibers," nominal molecular exclusion limit = 50,000
daltons, 0.5 mm internal diameter, 6 mm length, Amicon Corp., Lexington, MA)
were implanted in rat kidneys. Each tubule was filled with Ni3S2 by the following
procedure: (a) the empty tubule was weighed, (b) a tiny wad of cotton was inserted
in one end, (c) the partially plugged end of the tubule was connected to suction via a
blunt needle, (d) Ni3S2 powder was aspirated into the tubule from a weighing boat,
(e) the cotton wad was removed, (f) the tubule was reweighed to determine the Ni3S2
content, and (g) both ends were sealed by application of forceps that had been
heated in a flame. A No. 18 gauge needle was inserted into the rat kidney to a depth
of 8 mm, with care to avoid the renal calyx. The needle was withdrawn, and the
tubule was gently pushed into the renal parenchyma along the needle track.
Hematological Tests
Blood samples (- 50 1l) were obtained from tails of rats and gerbils, from toepads
of guinea pigs, and from retro-orbital venous plexuses of mice and hamsters. The
blood samples were collected in heparinized capillary tubes; microhematocrit deter-
minations were performed by the method of Strumia et al. [24]. Bioassays of
erythropoietin (Ep) activity were performed upon serum and renal extracts from
groups of 12 to 28 rats. The rats were exsanguinated by cardiocentesis, and 2 ml
samples of serum from each rat were pooled. Each kidney was perfused in situ with
12 ml of cold phosphate-buffered NaCl solution (Na2HPO4-KH2PO4 buffer, pH
7.0, 10 mmol/liter; NaCl, 0.14 mol/liter, 4°C). The kidneys were homogenized in
phosphate-buffered NaCl solution and centrifuged at 2300 xg for 30 minutes, as
described by Fried et al. [25]. Each ml of renal extract corresponded to 0.33 g of
kidney (wet weight). Each sample of pooled rat serum and pooled renal extract was
apportioned into 12 tubes; the tubes were stored at -20°C; one tube was thawed im-
mediately prior to each dosing in the Ep bioassay. Ep activity was measured in
groups of four to six post-hypoxic polycythemic mice, as previously described [6].
Each mouse received 12 injections sc of 0.5 ml of pooled serum, renal extract, or Ep
standard solution at six-hour intervals for three days (total dose = 6 ml per mouse).
Ep activities of rat serum and renal extract were read from a six-point logit calibra-
tion plot of erythrocyte "9Fe-uptake in mice that received injections of sheep Ep
standard solutions (8 to 500IU/liter). The Ep detection limit was 12IU/liter, de-
fined as the concentration of Ep that yielded a response differing by its standard
deviation multiplied by Student's t value for p = 0.05 from the response for "zero"
dose (NaCl vehicle solution) [6]. Null hypothesis for differences between observa-
tions in treated and control groups were tested by Student's t test [26].
RESULTS
Species Susceptibility Experiment
Blood hematocrit was measured in groups of rats, hamsters, gerbils, and guinea
pigs at one to four months after unilateral ir injection of Ni3S2 at dosages specified
in Table 1. Control groups received ir injection of NaCl vehicle. No significant
changes of blood hematocrit were observed in Ni3S2-treated hamsters and gerbils;
significant increases of blood hematocrit were found in Ni3S2-treated rats and guinea
pigs throughout the period of study. For example, at two months after ir injection of
Ni3S2, the average increase of blood hematocrit in rats was 46 percent and that in
guinea pigs was 38 percent, (p < 0.001 vs. corresponding values in controls).
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TABLE 1
Effects of ir Injection of Ni3S2 on Blood Hematocrit in Rodents
Blood Hematocrit (No) after ir Injection
Dose (ir) No. (mean + standard deviation)
of Ni3S2 of
Species (mg/animal) Animals I mo 2 mo 3 mo 4 mo
Rat Oa 11 50 + 2 48 ± 2 52 ± 3 51 4 2
5 11 64 2c 70 3c 72 3c 69 4c
Hamster Oa 12 56 2 52 3 54 1 54 2
5 10 57 2 58 4 57 3 53 3
Gerbil 0" 12 46 4 50 2 49 2 48 2
5 12 48 2 50 2 49 2 48 2
Guinea pig 0. 11 46 2 49 1 48 1 47 2
20 8 62± 7 67± 6 63± 8 53 6b
aNaCl vehicle (0.14 mol/liter) was injected into the right kidney of controls (0.1 ml/rat, hamster, or
gerbil; 0.25 ml/guinea pig).
bp < 0.05 vs. corresponding value in vehicle controls.
'p < 0.001 vs. corresonding value in vehicle controls.
Injection Route Experiment
Groups of rats were given intrasplenic or intrarenal injections of NaCl vehicle or
Ni3S2 (10 mg/rat). As indicated in Table 2, blood hematocrit values were consis-
tently increased at one to four months after ir injection of Ni3S2 (p < 0.001),
whereas blood hematocrit values did not change significantly after intrasplenic ad-
ministration of Ni3S2.
Splenectomy Experiment
Splenectomy or sham splenectomy (with exposure and palpation of the spleen)
were performed in groups of rats at five days before or after ir injection of NaCl
vehicle or Ni3S2 (5 mg/rat) (Table 3). Splenectomy had no effect upon blood
hematocrit values in vehicle-treated controls. Splenectomy did not suppress the
development of erythrocytosis in Ni3S2-treated rats.
Nephrectomy Experiment
Groups of rats were subjected to unilateral nephrectomy on the fourth day after
injection of NaCl vehicle or Ni3S2 (5 mg/rat) into the right kidney (Table 4). Exci-
TABLE 2
Blood Hematocrit of Rats after Intrasplenic or Intrarenal Injection of Ni3S2
Blood Hematocrit (Wo) after the Injection
Dose of No. (mean + standard deviation)
Injection Ni3S2 of
Site (mg/rat) Rats 1 mo 2 mo 3 mo 4 mo
Intrasplenic 0. 12 51 3 52 ± 2 53 2 48 2
Intrasplenic 10 12 50 3 48 3 53 5 48 2
Intrarenal Oh 12 51 ±1 51 2 51 2 50 1
Intrarenal 10 6 68 4c 75 4c 75 4c 74 6c
aNaCi vehicle (0.14 mol/liter, 0.2 ml/rat) was injected into the spleen.
bNaCl vehicle (0.14 mol/liter, 0.1 ml/rat) was injected into the right kidney.
cp < 0.001 vs. corresponding value in vehicle controls.
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TABLE 3
Effect of Splenectomy on Ni3S2-Induced Erythrocytosis in Rats
Blood Hematocrit (Wo) after ir Injection
Dose(ir) No. (mean + standard deviation)
of Ni3S2 of
Treatment (mg/rat) Rats 1 mo 2 mo 3 mo 4 mo
Sham splenectomya 0 10 48 ± 2 49 ± 1 50 2 51 2
Sham splenectomya 5 9 62 6f 68 5f 70 6f 70 8f
Splenectomyb 0 11 52 2 48 2 52 3 51 2
Splenectomyb 5 12 59 4f 67 5' 69 6f 64 8'
Sham splenectomy, Oe 11 48 4±2 48 4 2 51 2 52 3
Sham splenectomyc 5 11 64 ± 2f 70 ± 3f 72 A 3f 69 ± 4f
Splenectomyd Oe 12 49 2 49 2 51 3 50 1
Splenectomyd 5 10 62 4f 70 6' 71 7f 66 6f
aSham splenectomy five days before the ir injection.
bSplenectomy five days before the ir injection.
cSham splenectomy five days after the ir injection.
dSplenectomy five days after the ir injection.
eNaCl vehicle (0.14 mol/liter, 0.1 ml/rat) was injected into the right kidney of controls.
fp < 0.001 vs. corresponding value in vehicle controls.
sion of the right kidney completely prevented Ni3S2-induced erythrocytosis, while
excision ofthe left kidney had no effect. This experiment demonstrates that presence
of the injected kidney is essential for Ni3S2-induced erythrocytosis. The rats in this
experiment were killed at two months after ir injection, in order to perform
histological studies (McCully et al., manuscript in preparation).
Chelation Experiment
Sodium diethyldithiocarbamate and d-penicillamine were administered to rats by
sustained sc infusions, according to the schedule in Table 5. The molar dosage of
diethyldithiocarbamate was twice that of d-penicillamine, since the stoichiometric
ratios of Ni[II]-bis-diethyldithiocarbamate and Ni[II]-penicillamine are 1:2 and 1:1,
respectively. Diethyldithiocarbamate and d-penicillamine did not affect blood
hematocrit values in rats that received ir injection of NaCl vehicle. Administration of
diethyldithiocarbamate partially suppressed Ni3S2-induction oferythrocytosis, while
d-penicillamine had no effect.
TABLE 4
Effect of Nephrectomy on Ni3S2-Induced Erythrocytosis in Rats
Blood Hematocrit (%)
Dose (ir) No. (mean ± std. deviation)
of Ni3S2 of
Nephrectomy, (mg/rat)b Rats 1 mo 2 mo
None 0 10 52 2 53 ±2
None 5 10 70 3c 75 ±3c
Right 0 10 50 ±2 50±4 1
Right 5 10 49 ± id 49 ± 2d
Left 0 10 50 ±2 50±i-1
Left 5 10 70 5c 76±4 3c
aNephrectomy four days after ir injection.
bInjection of NaCl vehicle (0.14 mol/liter, 0.2 ml/rat) or Ni3S2 into the right kidney.
cp < 0.001 vs. corresponding value in vehicle controls.
dp < 0.001 vs. corresponding value in Ni3S2-treated controls.NI3 S2-INDUCED ERYTHROCYTOSIS IN RODENTS
TABLE 5
Effect of Chelating Agents on Ni3S2-Induced Erythrocytosis in Rats
Blood Hematocrit (No) after ir Injection
Dose(ir) No. (mean i standard deviation)
of Ni3S2 of
Treatment (mg/rat) Rats 1 mo 2 mo 3 mo 4 mo
Buffera Od 8 46 3 51 3 52 3 54 2
Buffera 1.2 6 56 5Y 70 4' 71 6' 70 6'
PENb Od 7 47 2 48 2 49 3 50 2
PENb 1.2 7 60 4' 69 5' 75± 7 71 11'
DDCc Od 8 45 2 51 2 51 3 52 2
DDCc 1.2 8 46 2i 62A 6fh 62± 8k 59 6oh
aPhosphate buffer (Na2HPO4-KH2PO4, 0.1 mil/liter, pH 9) was administered to controls (24 Il/day)
by an osmotic minipump implanted sc one day prior to the ir injection. The minipump was replaced at
seven-day intervals; the sc infusion was maintained for 35 days.
bd-Penicillamine (0.9 mol/liter in phosphate buffer) was infused sc (22 Amol/day) for 35 days (total
dose = 0.75 mmol/rat).
cSodium diethyldithiocarbamate (1.8 mol/liter in phosphate buffer) was infused sc (44 Amol/day) for
35 days (total dose = 1.5 mmol/rat).
,'NaCl vehicle (0.14 mol/liter, 0.2 ml/rat) was injected into the right kidney.
ep < 0.01 vs. corresponding value in controls that received phosphate buffer (sc) and NaCl vehicle
(ir).
'p < 0.001 vs. corresponding value in rats that received phosphate buffer (sc) and NaCl vehicle (ir).
8p < 0.05 vs. corresponding value in rats that received phosphate buffer (sc) and Ni3S2 (ir).
hp < 0.01 vs. corresponding value in rats that received phosphate buffer (sc) and Ni3S2 (ir).
ip < 0.001 vs. corresponding value in rats that received phosphate buffer (sc) and Ni3S2 (ir).
Metal Interactions Experiment
Four metal dusts (Mn, Cr, Cu, and Al) were administered to groups of rats by ir
injection (8 mg/rat), alone, or in combination with Ni3S2 (2.5 mg/rat). In the
absence of Ni3S2, the four metal dusts had no significant effects upon blood
hematocrit values (Table 6). Consistent with previous findings [16], induction of
erythrocytosis at one and two months after ir injection of Ni3S2 was partially sup-
pressed by admixture of Mn dust. Similar, but less marked, suppression of Ni3S2-
induced erythrocytosis was also noted at one month after ir injection ofCu dust and
Ni3S2, and at four months after ir injection of Al dust and Ni3S2. Enhancement of
erythrocytosis was observed at two to four months after ir injection of Cr dust and
Ni3S2, compared to that produced by Ni3S2, alone.
Semi-Permeable Tubule Experiment
Blood hematocrit values of rats were increased at one to four months after ir im-
planation of sealed cellulose tubules that contained 10 mg of Ni3S2 (Table 7). This
observation indicates that phagocytosis of Ni3S2 particles is not essential for Ni3S2-
induced erythrocytosis. Blood hematocrit values were also increased in rats at one to
four months after ir implantation of Ni3S2-containing tubules that had been punc-
tured 20 times with a needle. However, hematocrit values in these rats were not
significantly higher than in rats that received ir implants of sealed Ni3S2-containing
tubules.
Effect ofIron-Dextran Treatment
To ascertain whether augmentation of body iron stores might influence Ni3S2-
induced erythrocytosis, iron-dextran complex ("Imferon") was administered to rats
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TABLE 6
Effect of Metal Dusts upon Ni3S2-Induced Erythrocytosis in Rats
Blood Hematocrit (Olo) after ir Injection
Dose (ir) Dose(ir) No. (mean ± standard deviation)
of Metals of Ni3S2 of
(mg/rat) (mg/rat) Rats 1 mo 2 mo 3 mo 4 mo
0 (vehicle)a 0 9 50 1 49 A 2 49 3 50 1
8 (Mn dust)b 0 12 49 3 51 2 50 1 50 3
8 (Cr dust)b 0 12 52 2 49 2 52 2 50 2
8(Cudust)b 0 12 48 3 49 2 51 2 51 2
8 (Al dust)b 0 12 47 ± 2 51 2 52 3 52 2
0(vehicle) 2.5c 11 65 3 72 3 72 ± 4 69 5
8 (Mn dust)d 2.5 11 50 2f 65± 6 70 7 70 6
8 (Cr dust)d 2.5 12 66 3 77 3 Y 78 3' 76± 4
8 (Cu dust)d 2.5 12 59 5' 71 + 8 72 8 72 9
8 (Al dust)d 2.5 12 64 5 71 ± 4 68 5 58 5'
aNaCl vehicle (0.14 mol/liter, 0.2 ml/rat) was injected into the right kidney.
bThe metal dusts were injected in the right kidney in 0.2 ml of NaCl vehicle.
cNi3S2 was injected in the right kidney in 0.2 ml of NaCl vehicle.
dThe metal dusts plus Ni3S2 were injected in the right kidney in 0.2 ml of NaCl vehicle.
ep < 0.01 vs. corresponding value in rats that received Ni3S2 without added metal dust.
'p < 0.001 vs. corresponding value in rats that received Ni3S2 without added metal dust.
by nine biweekly im injections, commencing one week prior to ir injection of NaCl
vehicle or Ni3S2, as specified in Table 8. In the absence of Ni3S2 treatment, Imferon
administration had no significant effect upon blood hematocrit values. In contrast,
rats that received im Imferon plus ir Ni3S2 had substantially higher hematocrit values
than rats that received only Ni3S2.
Benzo(a)pyrene Interaction Experiment
Intrarenal injection of benzo(a)pyrene had no significant effect on blood
hematocrit values in rats (Table 9). When a mixture of benzo(a)pyrene and Ni3S2
was administered ir to rats, benzo(a)pyrene partially inhibited Ni3S2-induced
erythrocytosis throughout the period from one to four months after the injection.
TABLE 7
Blood Hematocrit of Rats after ir Implantation of Ni3S2 in Cellulose Tubules
Blood Hematocrit (o) after ir Implanation
Dose of No. (mean ± standard deviation)
Ni3S2 of
Treatment (mg/rat) Rats 1 mo 2 mo 3 mo 4 mo
Empty tubulea 0 12 49 1l 50 ± 1 49 ± 2 50 4 ld
Sealed tubuleb 10 12 55 ±3' 59± 8 58 ± 9@ 55 i7d
Punctured tubulec 10 10 55 ± 5 66 ± 7 66 ± 10' 61 ± 8f
aImplantation of an empty tubule in the right kidney of controls.
bImplantation ir of a sealed tubule that contained Ni3S2 (10 mg/rat).
cImplantation ir of a tubule that contained Ni3S2 (10 mg/rat), and that was punctured 20 times with a
No. 30 gauge needle.
dp < 0.05 vs. corresponding value in controls.
ep < 0.01 vs. corresponding value in controls.
'p < 0.001 vs. corresponding value in controls.
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TABLE 8
Effect of Imferon on Ni3S2-Induced Erythrocytosis in Rats
Blood Hematocrit (Olo) after ir Injection
Dose (ir) No. (mean + standard deviation)
of Ni3S2 of
Treatment (mg/rat) Rats 1 mo 2 mo 3 mo 4 mo
Vehiclea 0c 12 50± 1 50±2 51±2 51 2
Vehiclea 10 11 65 + 5d 71 ± 4d 71 5 Sd 67 5 5d
Imferonb 0c 12 50 2 49 2 50 2 52 ±2
Imferonb 10 12 70 6d. 77 5da 76 4df 74 5d5
aNaCl vehicle (0.14 mol/liter, 0.1 ml/rat) was injected im one week before and 1, 3, 5, 7, 9, 11, 13, and
15 weeks after the ir injection.
bImferon (iron-dextran, 5 mg Fe/rat) was injected im one week before and 1, 3, 5, 7, 9, 11, 13, and 15
weeks after the ir injection.
cNaCl vehicle (0.14 mol/liter, 0.2 ml/rat) was injected ir into the right kidney.
dp < 0.001 vs. corresponding value in controls that did not receive Ni3S2.
ep < 0.05 vs. corresponding value in rats that received Ni3S2 without Imferon.
fp< 0.02 vs. corresponding value in rats that received Ni3S2 without Imferon.
sp < 0.01 vs. corresponding value in rats that received Ni3S2 without Imferon.
Suppression ofNi3S2-induced erythrocytosis was not observed when benzo(a)pyrene
was injected in the left kidney and Ni3S2 was injected in the right kidney.
Erythropoietin Bioassays
To determine whether increased Ep activity in serum of Ni3S2-treated rats is
associated with increased Ep activity in kidney, Ep bioassays were performed upon
pooled serums and renal extracts from rats killed at two weeks after ir injection of
Ni3S2 or NaCl vehicle solution (Table 10, Experiment A). Consistent with previous
findings [6,10,11], Ep activity was increased sixfold in serum of Ni3S2-treated rats
(p < 0.001 vs. controls). Ep activity in pooled extracts of right (injected) kidneys
TABLE 9
Blood Hematocrit of Rats after ir Injection of Benzo(a)pyrene (BP) and Ni3S2a
Blood Hematocrit (No) after ir Injection
Dose(ir) Dose(ir) No. (mean ± standard deviation)
of BP of Ni3S2 of
(mg/rat) (mg/rat) Rats I mo 2 mo 3 mo 4 mo
Ob 0 15 48 2 48 ± 2 49 ± 2 52 ±2
2 0 15 49 2 48 1 48 ± 2 52 2
0 2 16 66 + 3 78 ±6f 78±+ 4 77± 6
2c 2 16 49 ± 2h 61± 8e 65± 9 e 68± 8e
2d 2 16 63 ± 4' 74 5' 74 4' 72 6'
aAll rats received Imferon (iron-dextran, 5 mg Fe/rat, im) one week before and 1, 3, 5, 7, 9, and 11
weeks after the ir injection.
bGlycerol vehicle (50 percent, v/v; 0.2 ml/rat) was injected into the right kidney.
cBenzo(a)pyrene (2 mg/rat) and Ni3S2 (2 mg/rat) were administered as a single injection in 0.2 ml of
glycerol vehicle into the right kidney.
dBenzo(a)pyrene (2 mg/rat, in 0.2 ml ofglycerol vehicle) was injected into the left kidney, and Ni3S2 (2
mg/rat, in 0.2 ml of glycerol vehicle) was injected into the right kidney.
ep < 0.01 vs. corresponding value in controls that did not receive Ni3S2.
fp < 0.001 vs. corresponding value in controls that did not receive Ni3S2.
8p < 0.01 vs. corresponding value in rats that received Ni3S2 without benzo(a)pyrene.
hp < 0.001 vs. corresponding value in rats that received Ni3S2 without benzo(a)pyrene.
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TABLE 10
Erythropoietin Activity in Rat Serum and Renal Extract after ir Injection of Ni3S2
Dose (ir) No. Hematocrit Pooled No. of RBC "Fe EP Activity
of Ni3S2 of (%) Samples for Assay Uptake (0o)c (IU/liter)
Exp. (mg/rat) Rats (mean + SD) Ep Assayb Mice mean L SD mean X SD
A 0 24 48 I Serum 5 1.48 0.54 14 5
Right kidney 6 1.24 + 0.26 12 + 3
Left kidney 6 1.41 k 0.27 13 t 3
5 28 56 + 4d Serum 5 20.5 i 6.1p 80 + 23
Right kidney 6 1.35 :h 0.56 13 k 5
Left kidney 6 1.31 h 0.33 12 X 3
B 0 12 48 + 2 Right kidney 5 1.55 + 0.23 14 + 3
Left kidney 5 2.87 + 1.18 24 + 8
5 12 56 + 4d Right kidney 4 2.80 + 0.43 23 X 5
Left kidney 5 1.93 + 0.14 17 X 2
aRats were killed two weeks after injection of NaCl vehicle (0.14 mol/liter, 0.2 ml/rat) or Ni3S2 in the
right kidney.
bPooled serums or renal extracts were administered to post-hypoxic polycythemic mice as 12 sc injec-
tions (0.5 ml/mouse at six-hour intervals during three days; total dose = 6 ml/mouse).
C"9Fe-labelled ferrous citrate solution (2ACi 59Fe/mouse) was injected iv at eight hours after the last sc
injection of serum or renal extract; "9Fe-uptake into circulating erythrocytes was measured at 24 hours
after the ferrous citrate injection.
dp < 0.01 vs. corresponding value for control rats.
*p < 0.001 vs. corresponding value for pooled serum from control rats.
from Ni3S2-treated rats did not differ from (a) Ep activity in extracts of right (in-
jected) kidneys of NaCl-treated controls, or (b) Ep activity in left (non-injected)
kidneys ofNi3S2-treated rats. Repetition ofthe Ep bioassays in pooled renal extracts
from Ni3S2-treated and control rats (Table 10, Experiment B) also failed to disclose
any significant variations in renal Ep activities.
DISCUSSION
Species Specificity
The observation that Ni3S2-induced erythrocytosis occurs in guinea pigs as well as
in rats provides a new experimental animal for investigations of the erythropoietic
effects of ir injection of Ni3S2. Species variations in susceptibility to Ni3S2-
stimulation of erythropoiesis are clearly evident, since the present study of gerbils
and a previous study of BALBc mice and squirrels [7] show that these species are
refractory to Ni3S2-induction of erythrocytosis. In hamsters, blood hematocrit at
two months after ir injection of Ni3S2 averaged 12 percent greater than in controls;
this slight increase was not statistically significant. In future studies, we shall deter-
mine whether significant erythrocytosis develops in hamsters after ir injection of
larger doses of Ni3S2.
Role ofthe Spleen
The possible involvement of the spleen in Ni3S2-stimulation oferythropoiesis was
investigated, since splenomegaly and splenicerythroid hyperplasia occurin rats after
ir injection of Ni3S2 [9], and since the spleen has been proposed as an extrarenal
source oferythropoietin [27-29]. In the present study, intrasplenic injection ofNi3S2
did not affect blood hematocrit in rats, and splenectomy did not significantly in-
fluence the erythrocytosis that occurs after ir injection of Ni3S2. Therefore, the
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spleen does not play an essential role in the pathogenesis of Ni3S2-induced
erythrocytosis. The lack of erythropoietic response to intrasplenic injection of Ni3S2
is consistent with the previously reported lack of erythropoietic response to intra-
hepatic injection of Ni3S2 in rats following partial hepatectomy [7]. To date, ir
injection is the only route of Ni3S2 administration that has been found to evoke
erythrocytosis in rats.
Nephrectomy
McCully et al. [9] speculated that glomerular mesangial cells may be responsible
for Ep production in Ni3S2-treated rats, based upon the occurrence of
glomerulomegaly and hyperplasia ofmesangial cells in both kidneys ofrats at one to
18 weeks after unilateral ir injection of Ni3S2. The present nephrectomy experiment
shows that excision of the non-injected (left) kidney does not diminish the
erythropoietic response, whereas excision of the injected (right) kidney completely
prevents the response. The possible involvement of the contralateral kidney in the
pathogenesis of Ni3S2-induced erythrocytosis has not hitherto been investigated;
consistent with previous findings [10,11], presence of the injected kidney appears to
be essential for Ni3S2-induction of erythrocytosis. Since mesangial cell hyperplasia
occurs with equal intensity in both kidneys [9], the results of the nephrectomy ex-
periment militate against the hypothesis that hyperplastic mesangial cells are respon-
sible for Ep production in Ni3S2-treated rats.
Effects of Chelators
Studies in rats indicate that diethyldithiocarbamate is superior to d-penicillamine
for treatment of nickel carbonyl poisoning [22], but less effective than d-penicilla-
mine as an antidote for nickel chloride poisoning [39]. Ni[II]-bis-diethyldithiocarba-
mate is lipophilic and Ni[II]-penicillamine is hydrophilic; these differences in
chemical properties result in disparate effects of diethyldithiocarbamate and
penicillamine on the tissue distribution of 63Ni[II] [31]. The present study shows that
ip infusion of diethyldithiocarbamate partially suppresses the erythropoietic
response to ir injection ofNi3S2 in rats, whereas d-penicillamine has no inhibitory ef-
fect. The inhibitory action of diethyldithiocarbamate on Ni3S2-induced erythrocy-
tosis may be unrelated to its chelating affinity for nickel, since diethyldithiocarba-
mate also protects rats against the toxicity of carbon tetrachloride [32] and
dimethylnitrosamine [33].
Effects ofMetal Dusts
At one month after ir injection of Mn dust in combination with Ni3S2, Mn dust
completely blocks Ni3S2-induced erythrocytosis. The inhibitory effect of Mn dust on
erythropoietic stimulation by Ni3S2 is less marked at two months; the inhibition is no
longer significant at three months after the ir injection. Manganese has also been
reported to antagonize the actions of nickel in other experimental systems; (a) Mn
dust suppresses the carcinogenicity of Ni3S2 following im and ir administration to
rats [19,20]; (b) Mn dust blocks in vitro morphological transformation of Syrian
hamster embryo cells by Ni3S2 [34]; (c) Mn[II] protects organ cultures of mouse
trachea from Ni[II] toxicity [35]; (d) administration sc of Mn[II] blocks Ni[II] in-
duction of heme oxygenase activity in rat kidney [36,37]; (e) Mn[II] and Ni[1I] com-
pete for binding to identical sites on rabbit and human albumins [38]; and (f) Mn[II]
and Ni[II] exert antagonistic effects upon action potentials of myocardial fibers in
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dogs [39,40]. Manganese influences the intracellular distribution of nickel, since
ultrafiltrable 63Ni concentration in muscle cytosol is diminished in rats that receive
im injection of Mn dust and 63Ni3S2, in comparison to rats that receive im injection
of 63Ni3S2, alone [20]. The molecular mechanism of manganese-nickel antagonism
has not been identified.
The present study indicates that Cu and Al dusts suppress Ni3S2-induced erythro-
cytosis in rats at one month and four months, respectively, after ir injection. The in-
hibitory effect of Cu dust is particularly interesting, since Cu[II] displaces Ni[II]
from its binding site near the N-terminus of human albumin [41]. Enhanced
erythrocytosis was noted in the present study at two to four months after combined
ir injection of Cr dust and Ni3S2, compared to that produced by Ni3S2, alone. This
observation is consistent with a recent report that Cr[III] potentiates the toxic effects
of Ni[II] in cell cultures of murine fibroblasts [42].
Semi-Permeable Tubules
Stimulation of erythropoiesis was observed in the present study in rats that re-
ceived ir implants of Ni3S2 within semipermeable tubules (nominal molecular exclu-
sion limit = 50,000 daltons). The erythrocytosis was not significantly augmented
when Ni3S2-containing tubules were punctured several times with a needle prior to ir
implantation. In a pilot study that was reported previously [7], erythrocytosis did
not develop in five rats that received ir implants of Ni3S2 within sealed tubules with
larger pores (nominal molecular exclusion limit = 150,000 daltons). We attribute
the discrepancy between the results of the pilot study and the present experiment to
(a) improved implantation technique, with less peritubular hemorrhage, and (b) less
obstruction ofthe smaller pores by fibrin. Ni3S2 gradually dissolves within the lumen
of the cellulose tubules; Ni[II]-complexes with amino acids, peptides, and low
molecular weight proteins slowly diffuse through the pores into the renal paren-
chyma [7,43]. The present experiment demonstrates that phagocytosis of Ni3S2 par-
ticles within the renal parenchyma is not essential for the induction of
erythrocytosis.
Effects ofImferon and Benzo(a)pyrene
Supplementation of body iron stores by biweekly im administration of iron-
dextran ("Imferon") augmented erythrocytosis in rats after ir injection ofNi3S2. This
observation suggests that dietary intake of iron from Purina laboratory rat chow is
insufficient to sustain the maximal rate of erythrocyte production in Ni3S2-treated
rats. Reports of carcinogenic synergism between benzo(a)pyrene and nickel com-
pounds [21,44,45] prompted us to administer benzo(a)pyrene and Ni3S2 to rats,
singly and in combination, by ir injection. Instead of enhancing Ni3S2-induced
erythrocytosis, benzo(a)pyrene partially inhibited the erythropoietic response. This
finding provides a novel experimental system to investigate the metabolic interac-
tions of benzo(a)pyrene and nickel compounds.
Erythropoietin Bioassays
Renal extracts, prepared by the method of Fried et al. [25], and pooled serums
from Ni3S2-treated and control rats were assayed for Ep activity in post-hypoxic
polycythemic mice. The bioassays demonstrated increased Ep activity in serum, but
not in renal extracts ofNi3S2-treated rats. This finding is consistent with the concept
that a renal erythropoietic factor ("erythrogenin") is produced by the kidney and
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acts in concert with a serum component to produce the active Ep molecule [46,47].
Meagher [10] detected increased erythrogenin activity in the light mitochondrial
fraction from injected kidneys ofNi3S2-treated rats. Attempts to confirm Meagher's
observation and to investigate the mechanism whereby Ni3S2 stimulates renal
erythrogenin activity are under way in our laboratory.
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